









市场行情
/
股票
/
nasdaq-hrow
/

Harrow Inc

HROW

47.167USD

-0.023-0.05%

交易中（美东）报价延迟15分钟

1.75B总市值

亏损市盈率 TTM



Harrow Inc

47.167

-0.023-0.05%

概览公司财务分析

概览

公司

财务

分析

关于 Harrow Inc 公司

Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Harrow Inc简介



公司代码HROW

公司名称Harrow Inc

上市日期Feb 08, 2013

CEOMullery (Frank)

员工数量382

证券类型Ordinary Share

年结日Feb 08

公司地址1A Burton Hills Blvd

城市NASHVILLE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编37215

电话16157334731

网址https://www.harrow.com/

公司代码HROW

上市日期Feb 08, 2013

CEOMullery (Frank)

Harrow Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Mark L. Baum, J.D.

Chairman of the Board, Chief Executive Officer

2.99M

+100006.00%

Mr. Andrew R. Boll

President, Chief Financial Officer, Company Secretary

811.18K

+33335.00%

Mr. Perry J. Sternberg

Lead Independent Director

Dr. Adrienne L. Graves, Ph.D.

Independent Director

Mrs. Lauren P. Silvernail

Independent Director

Mr. Amir Shojaei, Ph.D.

Chief Scientific Officer

Mr. Randall E. Pollard, CPA

Chief Accounting Officer

Mr. Frank Mullery

Chief Executive Officer of ImprimisRx

名称

名称/职务

职务

持股

持股变动

Mr. Mark L. Baum, J.D.

Chairman of the Board, Chief Executive Officer

2.99M

+100006.00%

Mr. Andrew R. Boll

President, Chief Financial Officer, Company Secretary

811.18K

+33335.00%

Mr. Perry J. Sternberg

Lead Independent Director

Dr. Adrienne L. Graves, Ph.D.

Independent Director

Mrs. Lauren P. Silvernail

Independent Director

Mr. Amir Shojaei, Ph.D.

Chief Scientific Officer

收入明细

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Product Sales Net

71.50M

0.00%

Transfer of acquired product sales/profit

141.00K

0.00%

由于公司未披露，未能获取相关数据

业务

地区

业务USD

名称

营收

占比

Product Sales Net

71.50M

0.00%

Transfer of acquired product sales/profit

141.00K

0.00%

股东统计

更新时间: 11月25日周二

持股股东

股东类型

持股股东

占比

Opaleye Management Inc.

10.49%

Baum (Mark L)

8.06%

BlackRock Institutional Trust Company, N.A.

6.02%

The Vanguard Group, Inc.

5.03%

Private Capital Management

5.01%

其他

65.39%

持股股东

占比

Opaleye Management Inc.

10.49%

Baum (Mark L)

8.06%

BlackRock Institutional Trust Company, N.A.

6.02%

The Vanguard Group, Inc.

5.03%

Private Capital Management

5.01%

其他

65.39%

股东类型

持股股东

占比

Investment Advisor

20.76%

Investment Advisor/Hedge Fund

19.70%

Individual Investor

16.06%

Hedge Fund

14.61%

Research Firm

2.10%

Pension Fund

0.83%

Bank and Trust

0.36%

Insurance Company

0.03%

Private Equity

0.02%

其他

25.53%

机构持股



更新时间: 1月1日周四

报告期

机构数

持股数

持股占比

持股变动

2025Q4

368

21.63M

58.41%

-2.17M

2025Q3

360

21.75M

58.77%

-3.27M

2025Q2

345

26.63M

72.57%

-2.99M

2025Q1

354

25.78M

70.87%

-4.22M

2024Q4

350

26.13M

73.38%

-4.49M

2024Q3

325

25.90M

72.95%

-2.80M

2024Q2

296

24.70M

70.19%

-6.36M

2024Q1

284

26.34M

74.95%

-7.20M

2023Q4

279

28.26M

80.94%

-4.94M

2023Q3

275

28.51M

81.73%

-152.59K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Opaleye Management Inc.

3.90M

10.54%

Sep 30, 2025

Baum (Mark L)

2.99M

8.06%

+100.01K

+3.47%

Dec 12, 2025

BlackRock Institutional Trust Company, N.A.

2.23M

6.02%

-24.19K

-1.07%

Sep 30, 2025

The Vanguard Group, Inc.

1.86M

5.03%

+131.00

+0.01%

Sep 30, 2025

Private Capital Management

1.86M

5.01%

-89.70K

-4.61%

Sep 30, 2025

Kaufman (Daniel)

1.68M

4.55%

-222.91K

-11.69%

Aug 12, 2024

Boll (Andrew R)

811.18K

2.19%

+33.34K

+4.29%

Dec 12, 2025

State Street Investment Management (US)

794.28K

2.14%

+21.18K

+2.74%

Sep 30, 2025

Geode Capital Management, L.L.C.

775.64K

2.09%

-35.16K

-4.34%

Sep 30, 2025

Royce Investment Partners

533.01K

1.44%

-20.68K

-3.73%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

State Street SPDR S&P Pharmaceuticals ETF

2.08%

Invesco Dorsey Wright Healthcare Momentum ETF

0.68%

First Trust Small Cap Growth AlphaDEX Fund

0.63%

iShares U.S. Pharmaceuticals ETF

0.46%

Invesco Dorsey Wright SmallCap Momentum ETF

0.37%

iShares Micro-Cap ETF

0.23%

First Trust Small Cap Core Alphadex Fund

0.2%

First Trust Multicap Growth Alphadex Fund

0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.08%

Avantis US Small Cap Equity ETF

0.08%

State Street SPDR S&P Pharmaceuticals ETF

占比2.08%

Invesco Dorsey Wright Healthcare Momentum ETF

占比0.68%

First Trust Small Cap Growth AlphaDEX Fund

占比0.63%

iShares U.S. Pharmaceuticals ETF

占比0.46%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.37%

iShares Micro-Cap ETF

占比0.23%

First Trust Small Cap Core Alphadex Fund

占比0.2%

First Trust Multicap Growth Alphadex Fund

占比0.1%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0.08%

Avantis US Small Cap Equity ETF

占比0.08%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Harrow Inc的前五大股东是谁？



Harrow Inc 的前五大股东如下：
Opaleye Management Inc.持有股份：3.90M，占总股份比例：10.54%。
Baum (Mark L)持有股份：2.99M，占总股份比例：8.06%。
BlackRock Institutional Trust Company, N.A.持有股份：2.23M，占总股份比例：6.02%。
The Vanguard Group, Inc.持有股份：1.86M，占总股份比例：5.03%。
Private Capital Management持有股份：1.86M，占总股份比例：5.01%。